Trial Profile
Addition of tiagabine to second-generation antipsychotics in the treatment of recent-onset schizophrenia by modification of developmental reorganization of the prefrontal cortex
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Tiagabine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 05 Jun 2023 Planned End Date changed from 1 Sep 2022 to 1 Sep 2024.
- 05 Jun 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2024.
- 06 May 2021 Planned End Date changed from 1 Sep 2019 to 1 Sep 2022.